Summit Therapeutics (SMMT) Stock Forecast & Price Target

$17.87 -0.53 (-2.88%)

(As of 12/20/2024 05:40 PM ET)

Summit Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Summit Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for SMMT.

Consensus Price Target

$33.33
86.53% Upside

According to the 6 analysts' twelve-month price targets for Summit Therapeutics, the average price target is $33.33. The highest price target for SMMT is $44.00, while the lowest price target for SMMT is $23.00. The average price target represents a forecasted upside of 86.53% from the current price of $17.87.

Get the Latest News and Ratings for SMMT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors.

SMMT Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	5 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$33.33	$34.75	$29.67	N/A
Forecasted Upside	86.53% Upside	82.89% Upside	35.40% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Buy	N/A

Rare "crisis signal" triggers for third time in U.S. market (Ad)

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details.

SMMT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SMMT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Summit Therapeutics Stock vs. The Competition

Type	Summit Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	86.53% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent SMMT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/11/2024	Wells Fargo & Company 3 of 5 stars	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00	+66.94%
12/6/2024	Jefferies Financial Group 2 of 5 stars		Initiated Coverage	Buy	$31.00	+76.94%
11/18/2024	HC Wainwright 2 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00	+140.31%
11/4/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$32.00	+68.51%
9/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$19.00 ➝ $23.00	+0.83%
9/25/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $40.00	+66.11%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:08 PM ET.

SMMT Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Summit Therapeutics is $33.33, with a high forecast of $44.00 and a low forecast of $23.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SMMT shares.
: According to analysts, Summit Therapeutics's stock has a predicted upside of 86.53% based on their 12-month stock forecasts.
: Over the previous 90 days, Summit Therapeutics's stock had 1 downgrade by analysts.
: Summit Therapeutics has been rated by research analysts at Citigroup, HC Wainwright, Jefferies Financial Group, JMP Securities, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.
: Analysts like Summit Therapeutics more than other "medical" companies. The consensus rating score for Summit Therapeutics is 2.83 while the average consensus rating score for "medical" companies is 2.81. Learn more on how SMMT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Rare "crisis signal" triggers for third time in U.S. market (Ad)

Click here for all the details.

This page (NASDAQ:SMMT) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Stock Forecast & Price Target